Category Added in a WPeMatico Campaign
CONCLUSION: Reduced glutathione combined with entecavir significantly improves liver function, reduces liver fibrosis, and enhances HBV-DNA clearance in chronic hepatitis B patients without increasing adverse reactions.
CONCLUSION: Cicaglocal can enhance wound healing and lead to improved clinical outcomes following Mohs micrographic surgery.
CONCLUSION: This study presents a novel surgical endoscopy technique for closing direct medial inguinal hernia defects and provides anatomical feasibility. The advantages of the technique include preventing seromas and severe postoperative pain. Further randomized studies are warranted to assess long-term results of this technique and establish clinical indications for its use in surgical practice.
CONCLUSIONS: Olaparib does not have sufficient single-agent activity to warrant further development in IDH-mutant CCA. However, a subgroup of patients demonstrated CB, and exploratory analysis revealed this subgroup to be enriched for lower baseline 2-HG levels. Future clinical trials leveraging the HRD properties of IDH mutations are warranted with enhanced patient selection and novel combination…
CONCLUSION: Alemtuzumab was feasible to administer in adults with ALL receiving intensive chemotherapy, but was without evidence of benefit.
CONCLUSION: CMRL is beneficial to improving residents’ ability of comprehensive analysis and prescribing medical orders as well as residents’ ability of communication skills and patient care in SRT. CMRL may be beneficial to improving the ability of clinical practice.
CONCLUSION: MHI was comparable to 99mTc in safety and SLN detection rates but differed in sensitivity on positive SLNs.
BACKGROUND: In the ARIEL4 trial of rucaparib versus standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma, the primary endpoint was met, showing improved investigator-assessed progression-free survival with rucaparib. Here, we present the final overall survival analysis of the trial and other post-progression outcomes.
CONCLUSION: In summary, using data from a recent RCT, TM was found to both improve health outcomes and reduce total costs in this analysis. Based on these results, further effectiveness trials and wider adoption of TM should be considered.
CONCLUSIONS: Durable guselkumab efficacy was sustained through 5 years of treatment among patient subpopulations irrespective of baseline disease severity or prior treatment history. J Drugs Dermatol. 2025;24(2):196-202. doi:10.36849/JDD.8344.